Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 875 versus OMNIPEN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 875 versus OMNIPEN N.
AUGMENTIN '875' vs OMNIPEN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
One 875 mg amoxicillin/125 mg clavulanate tablet orally every 12 hours.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
None Documented
None Documented
Amoxicillin: 1-1.5 hours (may extend to 7-13 hours in renal impairment). Clavulanate: ~1 hour (may extend to 2.5-4.5 hours in renal impairment).
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Amoxicillin: ~50-70% renal as unchanged drug, 10-20% biliary. Clavulanate: ~30-50% renal as unchanged, ~25% fecal.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic